Gilman Hill Asset Management’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.34M Sell
10,457
-400
-4% -$46.8K 0.18% 107
2026
Q1
$1.31M Sell
10,857
-370
-3% -$42.7K 0.2% 101
2025
Q4
$1.18M Buy
11,227
+875
+8% +$82.1K 0.19% 104
2025
Q3
$869K Buy
10,352
+14
+0.1% +$1.15K 0.14% 116
2025
Q2
$818K Sell
10,338
-1,225
-11% -$97.4K 0.13% 122
2025
Q1
$1.04M Sell
11,563
-309
-3% -$28.9K 0.18% 104
2024
Q4
$1.18M Sell
11,872
-975
-8% -$101K 0.21% 104
2024
Q3
$1.46M Sell
12,847
-396
-3% -$47K 0.24% 98
2024
Q2
$1.64M Buy
13,243
+1,175
+10% +$151K 0.3% 91
2024
Q1
$1.59M Sell
12,068
-86
-0.7% -$10.6K 0.29% 92
2023
Q4
$1.33M Sell
12,154
-105
-0.9% -$10.9K 0.25% 99
2023
Q3
$1.26M Sell
12,259
-5
-0% -$539 0.25% 100
2023
Q2
$1.42M Buy
12,264
+120
+1% +$13.6K 0.26% 99
2023
Q1
$1.29M Sell
12,144
-789
-6% -$85.2K 0.26% 96
2022
Q4
$1.43M Sell
12,933
-1,123
-8% -$115K 0.29% 92
2022
Q3
$1.21M Buy
14,056
+704
+5% +$62.8K 0.28% 99
2022
Q2
$1.22M Sell
13,352
-719
-5% -$63.7K 0.26% 95
2022
Q1
$1.16M Buy
14,071
+1,036
+8% +$81.7K 0.26% 94
2021
Q4
$999K Sell
13,035
-119
-0.9% -$9.48K 0.22% 103
2021
Q3
$988K Buy
13,154
+561
+4% +$42.7K 0.25% 94
2021
Q2
$979K Buy
12,593
+750
+6% +$55.8K 0.25% 93
2021
Q1
$871K Buy
11,843
+81
+0.7% +$5.97K 0.24% 96
2020
Q4
$918K Buy
11,762
+1,431
+14% +$109K 0.3% 84
2020
Q3
$818K Sell
10,331
-168
-2% -$13.2K 0.32% 79
2020
Q2
$775K Buy
10,499
+338
+3% +$25.4K 0.31% 85
2020
Q1
$746K Buy
10,161
+262
+3% +$20.6K 0.36% 81
2019
Q4
$859K Sell
9,899
-27
-0.3% -$2.22K 0.28% 91
2019
Q3
$797K Hold
9,926
0.27% 93
2019
Q2
$794K Buy
9,926
+236
+2% +$18.1K 0.27% 91
2019
Q1
$769K Buy
9,690
+524
+6% +$39.2K 0.27% 91
2018
Q4
$668K Sell
9,166
-361
-4% -$25.5K 0.28% 87
2018
Q3
$645K Sell
9,527
-1,397
-13% -$89K 0.25% 94
2018
Q2
$633K Buy
10,924
+1,016
+10% +$57.3K 0.26% 92
2018
Q1
$515K Buy
9,908
+535
+6% +$28.9K 0.23% 106
2017
Q4
$503K Buy
9,373
+52
+0.6% +$2.88K 0.2% 113
2017
Q3
$570K Sell
9,321
-2,035
-18% -$123K 0.23% 99
2017
Q2
$694K Sell
11,356
-654
-5% -$39.8K 0.3% 80
2017
Q1
$728K Sell
12,010
-5,505
-31% -$334K 0.32% 73
2016
Q4
$984K Sell
17,515
-1,068
-6% -$62.5K 0.36% 49
2016
Q3
$1.11M Buy
18,583
+2,547
+16% +$149K 0.43% 51
2016
Q2
$882K Sell
16,036
-970
-6% -$51.6K 0.36% 56
2016
Q1
$859K Sell
17,006
-1,284
-7% -$62.9K 0.39% 55
2015
Q4
$922K Sell
18,290
-171
-0.9% -$8.62K 0.45% 49
2015
Q3
$870K Buy
18,461
+95
+0.5% +$5.05K 0.45% 54
2015
Q2
$998K Buy
18,366
+5
+0% +$280 0.47% 53
2015
Q1
$1.01M Buy
18,361
+41
+0.2% +$2.32K 0.48% 53
2014
Q4
$993K Hold
18,320
0.5% 54
2014
Q3
$1.04M Sell
18,320
-1,104
-6% -$62K 0.56% 51
2014
Q2
$1.07M Buy
19,424
+42
+0.2% +$2.29K 0.56% 51
2014
Q1
$1.05M Buy
19,382
+4,701
+32% +$243K 0.62% 48
2013
Q4
$701K Buy
14,681
+1,048
+8% +$47.9K 0.46% 51
2013
Q3
$619K Sell
13,633
-4,213
-24% -$192K 0.45% 51
2013
Q2
$791K Buy
+17,846
New +$797K 0.58% 49

Other funds holding MRK

Gilman Hill Asset Management's MRK Position: Q2 2026 in Review

Gilman Hill Asset Management reduced its Merck (MRK) stake by 3.7% in Q2 2026, selling an estimated $46.8K and leaving 10,457 shares worth $1.34M. The position accounts for 0.18% of the portfolio, ranked #107.

Gilman Hill Asset Management first reported a position in MRK in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.64M in Q2 2024. 1,867 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Gilman Hill Asset Management held 10,457 shares of Merck worth $1.34M as of Q2 2026.
  • Gilman Hill Asset Management sold 400 Merck shares in Q2 2026, an estimated $46.8K.
  • Merck made up 0.18% of Gilman Hill Asset Management's portfolio in Q2 2026, its #107 holding.
  • Gilman Hill Asset Management first reported a position in Merck in Q2 2013 and has held it in 53 quarters since.
  • Gilman Hill Asset Management's Merck position peaked at $1.64M in Q2 2024.
  • 1,867 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Gilman Hill Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.